anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Anesthesia providers face numerous occupational hazards, including exposure to anesthesia gases, which can lead to fatigue. These professionals face challenges such as night shifts, OR stress, limited mobility and sunlight access, high workload, inadequate rest breaks. Health-related sociodemographic variables, such as smoking, sleep patterns, and obesity. Our research aims to explore various risk factors associated with fatigue among operating theatre workers including sleep quality.
METHODS: A cross-sectional study was conducted on 227 of operating room healthcare professionals from five tertiary hospitals in Saudi Arabia, for a period of 6 months, between January 1, 2023 to June 1, 2023. The study used a five-point Likert scale sheet and the FSS "fatigue severity scale" to analyze and measure fatigue and sleep quality. The questionnaire included all socio-demographic variables, work conditions, and fatigue severity scale items.
RESULTS: The major findings revealed a significant correlation between fatigue severity scores and exposure to anesthesia gases. Socio-demographic variables such as smoking have showed major relevance to fatigue in the sample size, as (76.6%) of the participants that answered as regular smokers have showed result of positive correlation to fatigue and with a significant of (0.034). Out of the total sample, 76.1% were exposed to anesthesia gases once daily, showing a positive association with fatigue severity scores. Work-related factors like job experience and position also had a lower association with fatigue severity. p (0.031) Univariate logistic regression p (0.035).
CONCLUSION: The study found that the work-related conditions like workload on Anesthesia technicians and technologists over 44 h per week and gas exposure is directly linked to fatigue severity and sleep quality so is the socio-demographic considerations. With poor sleep quality in younger staff which is documented in the study result a large-scale prospective analysis to understand the factors affecting OR staff's sleep quality and fatigue severity and what can be done to regulate working hours and break time and incorporate naps in to enhance patient safety and well-being for anesthesia providers in Saudi Arabia.
Group A: At time of sheath removal 15 ml. air is inflated in the TR-band. The sheath is removed. Air is deflated until bleeding, and 1-2 ml. air is then re-inflated to achieve hemostasis, and the volume air inflated is registered ("Initial inflated air volume"). Every 20 minutes 1/3 of the initial inflated air volume is deflated. If bleeding occurs then air is re-inflated until hemostasis and then additional 1-2 ml. air is inflated. This routine is repeated until hemostasis is achieved (TR-band fully deflated without bleeding).
The invention relates to a programmed-drug-release azobenzene derivative carrier, and a preparation method and application thereof. One end of azobenzene and derivative thereof of the carrier compound is connected with a cholesteryl group, and the other end is connected with a nitrogen heterocycle group. The chemical structural formula is disclosed in the specification, wherein R is alkyl group, aromatic ring group or H, R' is C1-3 alkyl group or H, n=1 or 2, and x=2-10. The preparation method comprises the following steps: diazo coupling, substitution, esterification, azanylation and the like. The novel azobenzene derivative can be used in the aspects of programmed-drug-release carriers and other photosensitive or temperature-sensitive stimulus-responsive materials. Compared with the prior art, the method provided by the invention is simple and easy to implement; and the prepared compound can be used in programmed-drug-release carriers and other photosensitive or temperature-sensitive stimulus-responsive materials, and has wide application prospects.
Pre-operative MBSR is a condition where individuals will receive a pre-operative 8-week community-based MBSR course, which includes group classes lasting 2.5 hours a week, 45-minutes of home practice 6 days per week, a 1-hour orientation session at the beginning, and a full-day silent retreat at the end. During the orientation, participants will complete the study measures for this study.
Young adults will consume the following breakfasts (in randomized order) for 7 days/pattern: 350kcal HP breakfasts (30g protein) in solid or beverage form or will skip breakfast. During the breakfast treatment periods, the participants will be provided with isocaloric breakfast meals containing 34% protein (30g protein), 40% CHO, and 26% fat. The participants will consume these meals each day throughout each of the 7 day testing periods. During the breakfast skipping treatment period, the participants will skip breakfast every morning with nothing to eat or drink (besides water) until 12:00 pm. During the acclimation days (i.e., days 1-6), participants will eat their breakfasts at home or work or simply skip the morning meal. An actigraph (to assess key indices of sleep) will be continuously worn and sleep diaries will be completed for all 7 testing days. During the afternoon of Day 3, the participant will arrive at the University of Missouri-Physical Activity and Wellness Center (MU-PAW) and fitted with a Continuous Glucose Monitor (CGM) measure glycemic control over the next 3 days. On day 6, the participant will complete hourly appetite questionnaires, consume a standardized dinner meal, and complete a salivary sample prior to sleep onset (sleep related hormones). On the 7th day of each pattern, the participants will report to the MU-PAW in the morning to complete the respective testing day. The participants will begin the testing day by either skipping breakfast or consuming their respective breakfast meal. Blood samples, salivary samples, and assessments of perceived appetite will be collected/completed at specific times throughout the day. Prior to lunch, a brain scan will be completed using functional magnetic resonance imaging (fMRI) to identify bain activation patterns in response to food pictures. Following the fMRI, the participants will be provided with an a standardized lunch. The participants will then complete the remainder of the testing day. An ad libitum food buffet will be provided for the participants to consume after their departure at home throughout the remainder of the day. . They will continue to wear the actigraph and eat/drink from the ad libitum packout cooler until going to bed that evening. Lastly, participants will complete a salivary sample and sleep diary immediately before bed. Between days 8-10, the participants will return all testing day equipment and the packout cooler, including all empty wrappers and any uneaten foods. A 3-7 day washout period will occur between patterns in which the participant will return to their habitual (i.e. pre-study) breakfast behaviors. Study outcomes include morning, mid-day, afternoon, and evening appetite, satiety, pleasure, perceived energy/sleepiness, hormonal responses (plasma glucose, insulin, ghrelin, PYY, melatonin, and cortisol concentrations), sleep indices (i.e total sleep time, sleep efficiency, perceived sleep quality), brain activation patterns, evening energy intake, and daily energy intake.
The recommended starting dose is 300 mg orally once daily. KORLYM must be given as a single daily dose. KORLYM should always be taken with a meal. Patients should swallow the tablet whole. Do not split, crush, or chew tablets. 

Dosing and titration

The daily dose of KORLYM may be increased in 300 mg increments. The dose of KORLYM may be increased to a maximum of 1200 mg once daily but should not exceed 20 mg/kg per day. Increases in dose should not occur more frequently than once every 2-4 weeks. Decisions about dose increases should be based on a clinical assessment of tolerability and degree of improvement in Cushing's syndrome manifestations. Changes in glucose control, anti-diabetic medication requirements, insulin levels, and psychiatric symptoms may provide an early assessment of response (within 6 weeks) and may help guide early dose titration. Improvements in cushingoid appearance, acne, hirsutism, striae, and body weight occur over a longer period of time and, along with measures of glucose control, may be used to determine dose changes beyond the first 2 months of therapy. Careful and gradual titration of KORLYM accompanied by monitoring for recognized adverse reactions [See Warnings and Precautions (5.1) and (5.2)] may reduce the risk of severe adverse reactions. Dose reduction or even dose discontinuation may be needed in some clinical situations. If KORLYM treatment is interrupted, it should be reinitiated at the lowest dose (300 mg). If treatment was interrupted because of adverse reactions, the titration should aim for a dose lower than the one that resulted in treatment interruption.
BACKGROUND: Amidst the COVID-19 pandemic, the learning pattern of medical students shifted from onsite to online. This transition may contribute to what has been called "Zoom fatigue." This study aimed to evaluate the prevalence of Zoom fatigue related to online learning, identify associated factors of Zoom fatigue, and explore its correlation with depression among medical students during the COVID-19 pandemic.
METHODS: This cross-sectional study was conducted among 1st to 6th-year Thai medical students. The online survey was administered using a demographic and health behavior questionnaire, the Patient Health Questionnaire-9 (PHQ-9), and the Thai version of the Zoom Exhaustion & Fatigue Scale (ZEF-T).
RESULTS: Among the 386 participating students, 221 (57%) were female, with a mean age of 20.6 years. The prevalence of high Zoom fatigue was 9.6%. In the multivariable regression analysis, a lower academic year and a higher number of online learning sessions were significant predictors of Zoom fatigue (p < 0.001), while regular exercise emerged as a protective factor (p = 0.009). The prevalence of depressive disorder was 61.9%, and a significant correlation was found between having a depressive disorder and experiencing Zoom fatigue (p = 0.004).
CONCLUSION: Zoom fatigue among medical students was correlated with depression. Consequently, medical students experiencing Zoom fatigue should undergo further assessment for depression. It is crucial to closely monitor medical students in lower academic years with a high number of online sessions for signs of Zoom fatigue. Additionally, implementing strategies, such as reducing the frequency of online sessions and promoting regular exercise, may help alleviate the symptoms.
The purpose of this multi-site, randomized, controlled trial is to determine the optimal frequency of repositioning nursing facility residents with mobility limitations who are at moderate and high risk for pressure ulcer development who are cared for on high density foam mattresses for the purpose of preventing pressure ulcers. Pressure ulcers result primarily from pressure over a bony prominence that occludes blood flow to tissues. Traditionally, soft surfaces over mattress and repositioning individuals every 2 hours to relieve pressure have been the gold standard of care to prevent ulcers. Recent improvements in support surfaces may reduce the need for 2-hour repositioning. The specific aims of this study are to determine if: 1) there is a significant difference in the incidence of pressure ulcers among: a) moderate risk (Braden Scale Score, 13-14) residents randomly assigned to be repositioned every 2-, compared with every 3- or 4- hours; or b) high risk (Braden Scale Score, 10-12) residents who are turned every 2- compared with every 3- or 4-hours; 2) mobility (spontaneous or assisted) measured by actigraphy is a significant covariate with repositioning frequency in the incidence of pressure ulcers and 3) resident characteristics and resident influencing factors are significant covariates of repositioning schedules on pressure ulcer incidence. A 2 X 2/2 X 3 experimental design is used in which participants at two levels of risk (moderate or high) for pressure ulcer development are randomly assigned to one of 3 repositioning schedules every 2-hours (the current standard of care), contrasted with 3- or 4- hours carried out for 3 weeks. Actigraphs worn for 7 days (Tuesday to Tuesday) will determine if mobility is a significant covariate. Residents (1080) who are over 65 years, able to give consent or have a surrogate who can give consent and are at moderate or high risk for pressure ulcers will be invited to participate. Nursing facilities are selected because of their ability to follow a research protocol and submit data according to protocol requirements, and who have a reputation for good care are being selected for participation. Participants will be randomly assigned to a repositioning schedule that will be carried out by a Certified Nursing Assistants (CNA) who will document time of each repositioning. A CNA supervisor monitors repositioning and documentation frequently. Data are FAXED to and monitored by the investigators daily. With the exception of the repositioning intervention, participants will receive the same preventive care as all residents. The primary outcome of this study, pressure ulcers (yes/no) will be documented by a nurse assessor who will be masked to the repositioning timing. Data analysis and management will be performed by ISIS. The goal of this study is to shape Nursing Facility policy by defining how level of risk, mobility, and frequency of repositioning of residents can reduce the incidence of pressure ulcers and improve resident outcomes. Less frequent repositioning would allow residents longer periods of sleep, would reduce staff time for repositioning, and allow more efficient allocation of time.
The following are claimed: (A) a method for detecting changes in immune function comprising comparing interleukin-2 (JL-2) prodn. by T helper cells in response to recall antigens selected from influenza A virus, tetanus toxoid, alloantigens and mouse xenogeneic antigens in human peripheral blood leukocytes (PBL) obtd. from a control gp. and an individual whose immune function needs to be tested, a deviation from the control value being indicative of immune dysfunction; (B) a method for distinguishing between different stages of immune dysfunction comprising (a) obtaining sepd. human PBL from a patient whose immune function needs to be detd. then washing the PBL twice in saline, resuspending in culture medium, counting with a haemocytometer and adjsuting to the desired concn. in tissue culture medium; (b) adding PBL to flat bottom plates and stimulating with influenza virus (FLU), tetanus toxoid (TET), mouse xenoantigens (XENO), alloantigens (ALLO) or phytohaemagglutinin (PHA) in the presence of anti-TAC monoclonal antibody (MAb) in a culture medium to allow prodn. of IL-2 and determining the resultant IL-2 content, a statistically significant difference between the stimulated PBL obtd. from the patient and unstimulated control PBL treated alike being an index of the stage of immune dysfunction; the IL-2 may be assayed by IL-2 dependent CTLL proliferation pulse labelled with 3H-thymidine. Also claimed are (C) a kit for testing in vitro function of T helper-antigen presenting cells; (D) methods for predicting organ transplant rejection and (E) method for determining pathway selective effects of an agent upon the immune system.
A composition for use in vascular relaxation, wherein the composition includes at least one polyunsaturated fatty acid component and at least one anthocyanin component. The polyunsaturated fatty acid component is an ethyl ester of the omega-3 fatty acids eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), or an amino acid salt of EPA or DHA. The anthocyanin component is cyanidin-3-galactoside, or delphinidin-3-arabinoside. Further, the omega-3 fatty acid salt has an organic counter ion which is lysine, arginine, ornithine and mixtures of the same. The composition further includes cyanidin-3-galactoside. The composition further includes fruits extracts or cereals extracts. A method for treating a disease with the composition.
FIELD: medicine, gynecology. SUBSTANCE: medicine, gynecology. Method solves the problem to create bactericidal concentrations not only in epithelia cells but in intercellular space where chlamydia are localized. Method uses combination of two antibiotics of different groups (macrolises, tetracyclines of wide spectrum) which is changed in 2-3 days for 8 days. Simultaneously local treatment is prescribed with a mix consisting of 15 ml 20%-dimexide solution, 1 g rifampicin, about 100 ml distilled water and ultraviolet irradiation onto perineum and vaginal areas at 1 biodose daily for 8 days. Before mix intake syringing is conducted with 5% sodium bicarbonate solution by soft urethral catheter introduced into posterior fornix, then a mix is administered. Local treatment is conducted daily at night period, ultraviolet irradiation - at daytime. EFFECT: high clinical efficiency.
Aims/Background Chronic renal failure (CRF) is the eventual outcome shared by various progressive renal diseases, posing a serious threat to the physical health of patients. CRF patients are required to undergo hemodialysis (HD), which imposes heavy psychological and mental burdens for most individuals. This study explores the effects of Internet Plus-based continuous nursing on the compliance of CRF patients with HD. Methods This study retrospectively analyzed the clinical data of 160 CRF patients undergoing HD in the Yantai Yuhuangding Hospital from March 2021 to April 2023, after excluding eight cases from an originally selected cohort of 168 cases. These patients were divided into two groups: 79 cases who received the routine nursing from March 2021 to March 2022 were categorized as the routine group, whereas 81 cases who were given Internet Plus-based continuous nursing from April 2022 to April 2023 were assigned into the observation group. The treatment adherence, self-management behaviors, quality of life and incidence of HD complications were compared in both groups. Results Both groups demonstrated no significant difference in the baseline information (p > 0.05). The scores of adherence in terms of HD attendance, medications, fluid restrictions and diet recommendations in the observation group were significantly higher than those in the routine group (p < 0.001). No significant difference in the Hemodialysis Self-Management Instrument (HDSMI) scores on the day of discharge between the two groups was found (p > 0.05). After 6 months of follow-up, the observation group showed significantly higher scores of partnership, problem solving, self-management execution and emotional processing than the routine group (p < 0.001). Both groups had no significant difference in the scores of Kidney Disease-Targeted Areas (KDTA) and 36-Item Short Form (SF-36) on the day of discharge (p > 0.05). After 6 months of follow-up, the scores of KDTA and SF-36 in the observation group were significantly higher than those in the routine group (p < 0.001). The incidence of HD complications in the observation group (7.41%) was significantly lower than that in the routine group (21.52%) (p < 0.05). Conclusion Internet Plus-based continuous nursing can effectively improve treatment adherence, self-management behaviors as well as quality of life in patients, and reduce the incidence of HD complications.
PROBLEM TO BE SOLVED: To obtain the subject inhibitor containing a pyridazine derivative represented by a specific formula, having inhibiting action on production or secretion of tumor necrosis factor and useful as a therapeutic medicine for cachexia or septic shock. SOLUTION: This inhibitor contains a pyridazine derivative of formula I  R1 is a halogen or AR10 [A is a single bond, O or NH, R10 is H, a (substituted) alkyl, a (substituted)alkenyl, etc.]; R2 and R3 are H, OH, a halogen, a (substituted)alkyl, etc.; R4 is a (substituted)alkyl, a (substituted)alkenyl, a (substituted)phenyl, etc.} or its salt, e.g. 1-(4-furoylpiperazin-1-yl)phthalazine, etc. Furthermore, the compound is preferably obtained by reacting well-known piridazine derivative of formula II with a piperazine derivative of formula III in an inert solvent at 0-200 deg.C and reacting the resultant compound with a carboxylic acid corresponding to R10 -A-H in an inert organic solvent in the presence of a base at 0-200 deg.C.
Reducing morbidity, length of hospital stay, and readmission rate are of paramount importance to improve patients' care. In the present paper, we aim to describe our experience in managing major oncologic thoracic surgery in clinical practice. This is a retrospective experience over the last 7 years. Data from 215 consecutive patients (performed by a single-team of two surgeon) undergoing thoracic surgery were reviewed and evaluated. The total hospital mean stay was 3,3 days. Complications were represented by 4 hemothorax, 1 pleural empyema without fistula, 3 arrhythmias (atrial fibrillation), 2 pnuemonias and 1 chylotorax. No 30-day severe surgery-related complication occurred, no mortality. In 169 Vats procedures, no convertion was necessary. We conclude that a united team work represented by two close-knit surgeons, with similar clinical background, propensity to share problems, no competitive behavior, allow to do faster surgery, to standardize the procedure improving the post-operative outcomes of cancer patients.
This study consists of Screening Phase, Observation Phase, Treatment Phase, Extension Phase, and Follow-up Phase. Screening assessments will be performed between 42 to 2 days before study drug administration. Observation Phase assessments will be performed a day before or on a day of the initial administration to confirm the eligibility of subjects. The eligible subjects will receive the repeated intravenous administration of E6011. E6011 will be dissolved in physiological saline (nearly 100 mL) for approximately 30-minute infusion. During the Treatment Phase, for the first and second cohorts, E6011 will be administered every 2 weeks up to Week 10, a total of 6 times (with a double dose at Week 0). For the third and fourth cohorts, E6011 will be administered at Weeks 0, 1 and 2, then every 2 weeks up to Week 10, a total of 7 times. Under no safety concerns, Crohn's Disease Activity (CDAI) is less than 150 or a decrease in CDAI from the Observation Phase is greater than 70 and a subject intends to continue administrations, the subject will receive a total of 20 subsequent biweekly administrations (40 weeks) at stable dose (Extension Phase). Subjects will be hospitalized for 24 hours after the initial and second administrations for postdose monitoring and will have out-patient monitoring until 12 weeks after the initial administration. If hospitalization is difficult after the second administration, the subjects can be held at the hospital for 6 hours and then allowed to go home after confirmation of the safety. Subjects who roll over onto the Extension Phase will have continued monitoring until 52 weeks after the initial administration. When the subjects complete (Week 12 or Week 52) or discontinue the study, they will undergo an on-site follow-up 28 days after the study completion or discontinuation and an off-site follow-up or telephone interview 70 days after the final administration. The investigator will conduct full assessments of subjects safety next day of the second administration (24 hours after the second administration) to confirm presence of absence of study-related manifestations which may affect the study drug administration of next cohort. When the sponsor is informed of investigator's judgment on the sixth subject in each cohort, the appropriateness of next cohort will be judged based on the safety data available including the judgment of individual investigator on the next day of the second administration.